thalidomide has been researched along with Acute Kidney Injury in 25 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Acute Kidney Injury: Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pomalidomide is an analog of thalidomide with immunomodulatory, anti-angiogenic, and anti-neoplastic activity indicated for the treatment of multiple myeloma refractory to at least two prior therapies." | 7.83 | A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use. ( Babalola, O; Baird, P; Devoe, CE; Hoang, H; Jhaveri, KD; Leung, S; Wanchoo, R, 2016) |
| " We report a case of a severe 'drug reaction with eosinophilia and systemic symptoms' syndrome associated with acute interstitial nephritis in a patient with multiple myeloma likely related to the administration of lenalidomide." | 7.80 | A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide. ( Guron, G; Layne, T; Shaaban, H, 2014) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 7.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| "In thalidomide treated mice, blood urea nitrogen (BUN) (59." | 5.62 | Thalidomide reduces glycerol-induced acute kidney injury by inhibition of NF-κB, NLRP3 inflammasome, COX-2 and inflammatory cytokines. ( Amirshahrokhi, K, 2021) |
| "Thalidomide treatment also significantly reduced tissue levels of the proinflammatory cytokines, MDA, MPO, and NO and increased anti-inflammatory cytokine IL-10." | 5.42 | Thalidomide ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in an experimental model. ( Amirshahrokhi, K; Khalili, AR, 2015) |
| "Pomalidomide is an analog of thalidomide with immunomodulatory, anti-angiogenic, and anti-neoplastic activity indicated for the treatment of multiple myeloma refractory to at least two prior therapies." | 3.83 | A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use. ( Babalola, O; Baird, P; Devoe, CE; Hoang, H; Jhaveri, KD; Leung, S; Wanchoo, R, 2016) |
| " We report a case of a severe 'drug reaction with eosinophilia and systemic symptoms' syndrome associated with acute interstitial nephritis in a patient with multiple myeloma likely related to the administration of lenalidomide." | 3.80 | A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide. ( Guron, G; Layne, T; Shaaban, H, 2014) |
| "Current chemotherapy for multiple myeloma is based on bortezomib (BOR), dexamethasone (DEX), and thalidomide (THA)." | 3.80 | Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ( Devine, E; Krause, B; Krieter, DH; Lemke, HD; Storr, M; Wanner, C, 2014) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 3.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| "Azotemia associated with the use of lenalidomide, a new and effective therapy for multiple myeloma, has not been reported in patients with multiple myeloma." | 3.74 | Azotemia associated with use of lenalidomide in plasma cell dyscrasias. ( Batts, ED; Hegerfeldt, Y; Lazarus, HM; Sanchorawala, V, 2008) |
| "The lenalidomide dose was adapted to the estimated glomerular filtration rate and dexamethasone was given at high dose in cycle one and at low dose thereafter." | 2.80 | Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. ( Adam, Z; Autzinger, EM; Greil, R; Heintel, D; Kasparu, H; Kuehr, T; Ludwig, H; Müldür, E; Poenisch, W; Rauch, E; Weißmann, A; Zojer, N, 2015) |
| "Patients with multiple myeloma aged older than 65 years have traditionally received an oral regimen combining melphalan and prednisone (MP)." | 2.45 | How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. ( Gay, F; Palumbo, A, 2009) |
| "In thalidomide treated mice, blood urea nitrogen (BUN) (59." | 1.62 | Thalidomide reduces glycerol-induced acute kidney injury by inhibition of NF-κB, NLRP3 inflammasome, COX-2 and inflammatory cytokines. ( Amirshahrokhi, K, 2021) |
| "Patients with multiple myeloma (MM) are at increased risk of arterial thrombosis." | 1.43 | Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. ( Hinduja, A; Limaye, K; Papanikolaou, X; Ravilla, R; Sasapu, A; Torbey, M; Waheed, S; Wei, L, 2016) |
| "Thalidomide treatment also significantly reduced tissue levels of the proinflammatory cytokines, MDA, MPO, and NO and increased anti-inflammatory cytokine IL-10." | 1.42 | Thalidomide ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in an experimental model. ( Amirshahrokhi, K; Khalili, AR, 2015) |
| "We herein present a case of multiple myeloma with Fanconi syndrome and acute kidney injury due to light chain proximal tubulopathy with light chain cast nephropathy." | 1.40 | Acquired Fanconi syndrome with proximal tubular cytoplasmic fibrillary inclusions of λ light chain restriction. ( Liu, G; Liu, L; Wang, SX; Wang, Y; Yao, Y; Zhang, YK, 2014) |
| "Acute kidney failure in multiple myeloma (MM) occurs in 12%-20% of patients and is a poor prognostic factor for patient survival." | 1.39 | Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure. ( Aljama, P; Alonso, C; Alvarez-Lara, MA; Caballero-Villarraso, J; Carracedo, J; Martín-Malo, A; Ojeda-López, R; Pendón-Ruiz de Mier, MV, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moia, R | 1 |
| Boggio, E | 1 |
| Gigliotti, L | 1 |
| Crisà, E | 1 |
| De Paoli, L | 1 |
| Margiotta Casaluci, G | 1 |
| Rolla, R | 1 |
| Patriarca, A | 1 |
| Gaidano, G | 1 |
| Dianzani, U | 1 |
| Bruna, R | 1 |
| Amirshahrokhi, K | 2 |
| Shaaban, H | 1 |
| Layne, T | 1 |
| Guron, G | 1 |
| Pendón-Ruiz de Mier, MV | 1 |
| Alvarez-Lara, MA | 1 |
| Ojeda-López, R | 1 |
| Martín-Malo, A | 1 |
| Carracedo, J | 1 |
| Caballero-Villarraso, J | 1 |
| Alonso, C | 1 |
| Aljama, P | 1 |
| Martín-Gómez, MA | 1 |
| García-Marcos, SA | 1 |
| Caba-Molina, M | 1 |
| Palacios-Gómez, ME | 1 |
| Gómez-Morales, M | 1 |
| Claver-Ferré, C | 1 |
| Krieter, DH | 1 |
| Devine, E | 1 |
| Wanner, C | 1 |
| Storr, M | 1 |
| Krause, B | 1 |
| Lemke, HD | 1 |
| Yao, Y | 1 |
| Wang, SX | 1 |
| Zhang, YK | 1 |
| Wang, Y | 1 |
| Liu, L | 1 |
| Liu, G | 1 |
| Khalili, AR | 1 |
| Hobeika, L | 1 |
| Self, SE | 1 |
| Velez, JC | 1 |
| Ludwig, H | 1 |
| Rauch, E | 1 |
| Kuehr, T | 1 |
| Adam, Z | 1 |
| Weißmann, A | 1 |
| Kasparu, H | 1 |
| Autzinger, EM | 1 |
| Heintel, D | 1 |
| Greil, R | 1 |
| Poenisch, W | 1 |
| Müldür, E | 1 |
| Zojer, N | 1 |
| Baird, P | 1 |
| Leung, S | 1 |
| Hoang, H | 1 |
| Babalola, O | 1 |
| Devoe, CE | 1 |
| Wanchoo, R | 1 |
| Jhaveri, KD | 1 |
| Kreiniz, N | 1 |
| Khateeb, A | 1 |
| Gino-Moor, S | 1 |
| Polliack, A | 1 |
| Tadmor, T | 1 |
| Hinduja, A | 1 |
| Limaye, K | 1 |
| Ravilla, R | 1 |
| Sasapu, A | 1 |
| Papanikolaou, X | 1 |
| Wei, L | 1 |
| Torbey, M | 1 |
| Waheed, S | 1 |
| Palumbo, A | 1 |
| Gay, F | 1 |
| Gozzetti, A | 1 |
| Crupi, R | 1 |
| Defina, M | 1 |
| Bocchia, M | 1 |
| Rosa, J | 1 |
| Sydor, A | 1 |
| Jurczyszyn, A | 1 |
| Zabawa-Hołyś, S | 1 |
| Nowak, J | 1 |
| Czapkowicz-Gryszkiewicz, L | 1 |
| Sułowicz, W | 1 |
| Hutchison, CA | 1 |
| Heyne, N | 1 |
| Airia, P | 1 |
| Schindler, R | 1 |
| Zickler, D | 1 |
| Cook, M | 2 |
| Cockwell, P | 2 |
| Grima, D | 1 |
| Stringer, S | 1 |
| Kastritis, E | 1 |
| Dimopoulos, MA | 1 |
| Bladé, J | 1 |
| Harris, E | 1 |
| Behrens, J | 1 |
| Samson, D | 1 |
| Rahemtulla, A | 1 |
| Russell, NH | 1 |
| Byrne, JL | 1 |
| Izzedine, H | 1 |
| Launay-Vacher, V | 1 |
| Deray, G | 1 |
| Terrier, B | 1 |
| Joly, D | 1 |
| Ghez, D | 1 |
| Knebelmann, B | 1 |
| Fakhouri, F | 1 |
| Hummel, A | 1 |
| Lommatzsch, SE | 1 |
| Bellizzi, AM | 1 |
| Cathro, HP | 1 |
| Rosner, MH | 1 |
| Patil, S | 1 |
| Schwarer, A | 1 |
| McLean, C | 1 |
| Batts, ED | 1 |
| Sanchorawala, V | 1 |
| Hegerfeldt, Y | 1 |
| Lazarus, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury: a Prospective Cohort Study[NCT05429515] | Phase 4 | 50 participants (Anticipated) | Interventional | 2022-07-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for thalidomide and Acute Kidney Injury
| Article | Year |
|---|---|
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 2009 |
Achieving an early myeloma response in patients with kidney impairment.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexa | 2012 |
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexa | 2012 |
1 trial available for thalidomide and Acute Kidney Injury
| Article | Year |
|---|---|
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anemia; Dexamethasone; Female; Glomerular Filtration R | 2015 |
21 other studies available for thalidomide and Acute Kidney Injury
| Article | Year |
|---|---|
Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bortezomi | 2020 |
Thalidomide reduces glycerol-induced acute kidney injury by inhibition of NF-κB, NLRP3 inflammasome, COX-2 and inflammatory cytokines.
Topics: Acute Kidney Injury; Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Cytokines; Glycerol; Infla | 2021 |
A case of DRESS (drug reaction with eosinophilia and systemic symptoms) with acute interstitial nephritis secondary to lenalidomide.
Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Aged; Drug Hypersensitivity Syndrome; Female; Humans; | 2014 |
Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.
Topics: Acute Kidney Injury; Adsorption; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids | 2013 |
Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Topics: Acute Kidney Injury; Anemia; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Drug | 2013 |
Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; | 2014 |
Acquired Fanconi syndrome with proximal tubular cytoplasmic fibrillary inclusions of λ light chain restriction.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acid | 2014 |
Thalidomide ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in an experimental model.
Topics: Acute Kidney Injury; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Blood Urea Nitrogen; | 2015 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Levofloxa | 2016 |
Acute Renal Failure Associated with Lenalidomide Treatment in Multiple Myeloma: A Rare Occurrence?
Topics: Acute Kidney Injury; Aged; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Mul | 2016 |
Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study.
Topics: Acute Kidney Injury; Antineoplastic Agents; Case-Control Studies; Cerebral Hemorrhage; Hospital Mort | 2016 |
Lenalidomide efficacy in bortezomib-resistant myeloma.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resis | 2010 |
[Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone | 2010 |
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Topics: Acute Kidney Injury; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Databases, Factual; | 2012 |
Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia.
Topics: Acute Kidney Injury; Aged; Angiogenesis Inhibitors; Female; Humans; Hyperkalemia; Male; Middle Aged; | 2003 |
Thalidomide for the nephrologist.
Topics: Acute Kidney Injury; Angiogenesis Inhibitors; Humans; Hyperkalemia; Thalidomide | 2005 |
Reversible paraparesis in multiple myeloma with renal failure.
Topics: Acute Kidney Injury; Combined Modality Therapy; Follow-Up Studies; Humans; Hyperkalemia; Kidney Func | 2006 |
Acute renal failure caused by renal infiltration by hematolymphoid malignancy.
Topics: Acute Kidney Injury; Allopurinol; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; D | 2006 |
Urinary cytology in multiple myeloma.
Topics: Acute Kidney Injury; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Fat | 2008 |
Azotemia associated with use of lenalidomide in plasma cell dyscrasias.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azotemia; Dexameth | 2008 |